Erasca (ERAS) Is Up 60.7% After Early ERAS-0015 Data Highlights Pan-RAS Franchise Ambitions [Yahoo! Finance]
Erasca, Inc. (ERAS)
Company Research
Source: Yahoo! Finance
for its pan-RAS degrader ERAS-0015 and continued progress for its pan-KRAS inhibitor ERAS-4001 in Phase 1 trials. This progress underscores Erasca's push to build a differentiated RAS-targeting franchise aimed at cancers with significant unmet medical need across multiple tumor types. Next, we'll examine how this early efficacy signal for ERAS-0015 shapes Erasca's investment narrative and future risk-reward profile. These 14 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs . Discover why before your portfolio feels the trade war pinch. To own Erasca here, you have to believe its RAS franchise can translate early signals into durable, registrationally relevant data before the cash runway runs down. The latest ERAS-0015 update meaningfully sharpens that narrative: confirmed and unconfirmed responses at low doses with clean safety and linear pharmacokinetics give the story more clinical substance and help explain the very large
Show less
Read more
Impact Snapshot
Event Time:
ERAS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ERAS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ERAS alerts
High impacting Erasca, Inc. news events
Weekly update
A roundup of the hottest topics
ERAS
News
- Erasca (ERAS) Touches 3-Year High as 4 Analysts Go Bullish; Gets 267% PT Hike [Yahoo! Finance]Yahoo! Finance
- Erasca (NASDAQ:ERAS) had its "overweight" rating reaffirmed by analysts at Piper Sandler.MarketBeat
- Assessing Erasca (ERAS) Valuation After Encouraging Early ERAS-0015 Data At JP Morgan Conference [Yahoo! Finance]Yahoo! Finance
- Erasca (ERAS) Climbs to 3-Year High as Analyst Hikes PT by 83% [Yahoo! Finance]Yahoo! Finance
- Erasca (ERAS) Hits Fresh High Anew as Firm Gets up to 267% PT Hike [Yahoo! Finance]Yahoo! Finance
ERAS
Earnings
- 11/12/25 - In-Line
ERAS
Sec Filings
- 1/15/26 - Form 144
- 1/14/26 - Form SCHEDULE
- 1/12/26 - Form 8-K
- ERAS's page on the SEC website